1 hr ago
Exclusive - Forest keen to bid for Irish drugmaker Elan - sources
The Federal Reserve on Wednesday said risks to the outlook for the U.S. economy and job market had eased since last fall, but it said it would keep buying $85 billion in bonds per month given the still-high level of unemployment.
Mon Jun 17, 2013
IRWD Launches Constella in Europe - Analyst Blog
Ironwood Pharmaceuticals, Inc. recently announced that it has launched Constella in collaboration with Almirall, S.A. in Europe.
US Launch of Forest's Namenda XR - Analyst Blog
Forest Laboratories, Inc. recently announced the launch of its Alzheimer's drug, Namenda XR, in the US.
Fri Jun 14, 2013
Forest Laboratories Price Target Increased to $48.00 by Analysts at Cantor Fitzgerald
The firm currently has a "buy" rating on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 16.85% from the stock's previous close.
Thu Jun 13, 2013
Ironwood drug for irritable bowel syndrome is now available in Europe
Ironwood Pharmaceuticals Inc. of Cambridge and its European partner, Almirall S.A. of Spain, said that a new Ironwood drug for irritable bowel syndrome with constipation is now available in Germany, the UK, and the Nordic countries.
Forest Announces U.S. Availability of New Once-Daily Namenda XR
Forest Laboratories, Inc. announced today that NAMENDA XR once-daily formulation is now available in pharmacies throughout the United States.
Wed Jun 12, 2013
Forest Laboratories Given New $48.00 Price Target at Jefferies Group
Jefferies Group's price target indicates a potential upside of 20.51% from the stock's previous close.
Tue Jun 11, 2013
Forest Laboratories Inc. Presents at Goldman Sachs 34th Annual Global ...
Francis I. Perier - Chief Financial Officer, Executive Vice President of Finance & Administration and Member of Disclosure, Legal Compliance & Risk Management Committee All right, we're going to start, everybody.
peHUB Second Opinion 6.11
Meanwhile, a Viola, New York man is outraged that his private information is being collected by someone other than advertisers.
UPDATE 1-Forest Labs to add Icahn aide to board, avert proxy fight
Forest Laboratories Inc said on Tuesday it will add a representative of Carl Icahn as an independent member to its board, averting a new proxy battle with the billionaire investor.
Mon Jun 10, 2013
Now Available: Acute Inflammation - Pipeline Review, H1 2013
This report provides information on the therapeutic development for Acute Inflammation, complete with latest updates, and special features on late-stage and discontinued projects.
Fri Jun 07, 2013
Exclusive: Forest braces for third bout with Icahn
Forest Laboratories Inc is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, according to two sources familiar with the situation.
Wed Jun 05, 2013
On The Fly: Analyst Upgrade Summary
Check below for free stories on APA;BHI;CTXS;COP;CRM;RHP;TKR;DCO;ACC;LMOS;INFA;JOEZ;FRX;BBG;KED;QEP;BBBY the last two weeks.
Argus Upgrades Forest Laboratories to Buy
The firm currently has a $46.00 target price on the stock. Argus' price objective would indicate a potential upside of 14.74% from the stock's previous close.
Tue Jun 04, 2013
The Dope On A Forest Labs Takeover
Carl Icahn lost a proxy battle in 2011 to leverage his 10% ownership stake into four seats on Forest Lab's board.
Mon Jun 03, 2013
Global Alzheimers Drugs Industry 2012-2016 Available Through MarketResearchReports.biz
TechNavio's analysts forecast the Global Alzheimer's Drugs market to grow at a CAGR of 3.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population.
Thu May 30, 2013
Ironwood Pharma rises following analyst upgrade Shares of Ironwood...
Shares of Ironwood Pharmaceuticals Inc. rose Friday after a Wedbush analyst upgraded the stock, saying growth in prescriptions for the company's bowel drug Linzess has been better than he expected.
Wed May 29, 2013
Forest Laboratories Upgraded to "Buy" at TheStreet
The analysts wrote, "Forest Laboratories has been upgraded by TheStreet Ratings from hold to buy.
As Forest Laboratories, Inc. CEO Plans Retirement, the Feds Issue a New Subpoena
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Around the same time that Howard Solomon decided that he will soon retire as the long-standing ceo at Forest Laboratories, the drugmaker received a subpoena from the US Department of Justice concerning its Turdorza Pressair treatment for chronic obstructive ... (more)
Mon May 27, 2013
The Motley Fool
2 Biotech Stocks in Activist Investors' Crosshairs
Activist investors are no stranger to the health-care sector, an industry known for binary events and buyouts.